Yesterday, the "Second Organoid Interdisciplinary Summit Forum and the Inauguration Ceremony of Shandong Huize Jikang Biomedical Technology Co., Ltd." was successfully held at the Dezhou Zhongyuan Technology Innovation and Entrepreneurship Park in Dezhou City, Shandong Province. The event was co-organized by the Dezhou Economic and Technological Development Zone Management Committee and Fudan University.
The commencement of operations at Huize Med signifies the official launch of bioGenous' Northern GMP Production Center.
The opening ceremony, held yesterday morning, was chaired and addressed by YUE Hongxing, Member of the Party Work Committee and Deputy Director of the Dezhou Economic and Technological Development Zone. ZHAO Bing, Chairman of Shandong Huize Jikang Biomedical Technology Co., Ltd. and a local Dezhou native, also delivered a speech reflecting on his entrepreneurial journey and determination to return to his hometown.
*ZHAO Bing, Chairman of Huize Med, delivered a speech
Chairman ZHAO Bing delivered a speech, expressing his gratitude for the strong support from the People’s Government of Dezhou Economic and Technological Development Zone and Zhongyuan Science and Technology Park. He emphasized that Huize Med has efficiently and steadily completed critical steps, such as the company’s establishment, enterprise-university joint R&D, and the development of reagent and technical service products, including small-scale and pilot tests. "Today, we are filled with great excitement as we announce the launch of Dezhou's first GMP Class B organoid-focused production base, marking a milestone in the development of Huize Med!"
*YUE Hongxing Delivered a speech
Director YUE Hongxing extended warm congratulations on the unveiling and operational launch of Huizee Med. In his speech, Director YUE highlighted that organoids, as an emerging cutting-edge technology in recent years, are an indispensable part of China's "Healthy China" strategy and a key component of Dezhou's biopharmaceutical industry and the 541 industrial system. He noted that Huizee Med new "tumor organoid culture technology, providing personalized precision medication guidance for cancer patients," has injected fresh vitality into the Dezhou Economic and Technological Development Zone. This breakthrough brings new momentum to the development of the medical and health industry in the zone. He expressed hope that the company will accelerate its construction efforts and achieve the expected benefits soon, setting a benchmark and model for Dezhou's biomedical development.
SONG Shizhong(Left), ZHAO Bing (Right)
During the subsequent unveiling ceremony, SONG Shizhong, Deputy Secretary of the Party Work Committee and Deputy Director of the Management Committee of Dezhou Economic and Technological Development Zone, together with ZHAO Bing, Chairman of Shandong Huize Jikang Biomedicine Technology Co., Ltd., jointly unveiled the company.
Shandong Huize Jikang Biomedicine Technology Co., Ltd. signed a cooperation agreement with Dezhou Vocational and Technical College.
Shandong Huize Jikang Biomedicine Technology Co., Ltd. signed a cooperation agreement with Dezhou Second People's Hospital.
Shandong Huize Jikang Biomedicine Technology Co., Ltd. signed a cooperation agreement with NanoPeptide (Qingdao) Biotechnology Ltd.
▼
After the ceremony, the attending leaders and guests visited the laboratory of Shandong Huize Jikang Biomedicine Technology Co., Ltd.
The Second Organoid Interdisciplinary Summit Forum
To promote the development of the organoid field in China, explore the critical applications of organoids in interdisciplinary basic and translational research, and advance the industrialization of interdisciplinary organoid research, the Second Organoid Interdisciplinary Summit Forum, co-hosted by the Dezhou Economic and Technological Development Zone Management Committee and Fudan University, officially opened this afternoon.
Professor ZHAO Bing, Chairman of Shandong Hui Ze Ji Kang Biomedicine Technology Co., Ltd. and Director of the Organoid Center at Fudan University, together with Wang Jihua, Dean of Dezhou College, XU Shicai, Dean of Dezhou College, Professor LIU Guofeng, and CAO Zhipeng, General Manager of NanoPeptide (Qingdao) Biotechnology Ltd., delivered keynote speeches.
The Necessity and Current Status of Organoid Standardization (ZHAO Bing)
Real-Time Monitoring Technology for Organoids Based on Nano-Sensors (LIU Guofeng)
Clinical Progress in Breast Cancer Organoid Tumor Drug Sensitivity (CAO Zhipeng)
The forum was packed with insightful talks and lively discussions, showcasing a wealth of knowledge and innovative perspectives on organoid development.
The forum was packed with insightful talks and lively discussions, showcasing a wealth of knowledge and innovative perspectives on organoid development. The five-hour event witnessed in-depth exchanges among experts, fostering productive discussions across academia, industry, and research parks. In his closing remarks, Professor ZHAO Bing summed up the key takeaways, marking the successful conclusion of the Second Organoid Interdisciplinary Summit Forum and the unveiling ceremony of Shandong Huize Jikang Biomedicine Technology Co., Ltd.
Shandong Huize Jikang Biomedicine Technology Co., Ltd. is a company that emerged from the successful incubation of Dezhou OrganRegen Biotech Co., Ltd., located within the innovation park. The project is led by Professor ZHAO Bing, Director of the Organoid Center at Fudan University, a recipient of the National Science Fund for Distinguished Young Scholars and the chief scientist of China's 973 Program. The company is committed to developing new technologies for tumor organoid culture, focusing on in vitro cultivation of patient-derived tumor organoids for drug sensitivity testing to provide personalized and precise medication guidance for cancer patients.
The project team boasts world-leading expertise in tumor organoid culture and drug sensitivity testing, holding seven core patents. They offer personalized medication guidance for patients with various types of cancer, including lung, colon, breast, and endometrial cancer. In the early stages, the project, based in Shanghai, completed its R&D and market groundwork, having already served hundreds of cancer patients.
Once fully operational, the company aims to provide services to 10,000 patients annually, with an estimated annual output value of RMB 200 million. Within three years of its establishment, the company expects to expand its market coverage across northern China and the entire country, serving 100,000 patients annually with an output value of RMB 2 billion. In five years, the company aims to go public on the STAR Market.
Original Link：
